These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 17285813)

  • 1. The use of therapeutic interchange for biologic therapies.
    Flood J; Mihalik C; Fleming RR; Strober BE; Zucker DR; Burgoyne DS
    Manag Care; 2007 Jan; 16(1):51-62. PubMed ID: 17285813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Issues in formulary management: therapeutic interchange. The value, cost, and quality of therapeutic interchange.
    Mahoney CD
    Hosp Formul; 1992 Oct; 27 Suppl 2():2-3. PubMed ID: 10122035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formulary management: antibiotics and therapeutic interchange.
    Massoomi F
    Pharm Pract Manag Q; 1996 Oct; 16(3):11-8. PubMed ID: 10166231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
    Mazzotta A; Esposito M; Costanzo A; Chimenti S
    Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy.
    Yazici Y; Shi N; John A
    Bull NYU Hosp Jt Dis; 2008; 66(2):77-85. PubMed ID: 18537774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Considerations for assessing the cost of biologic agents in the treatment of psoriasis.
    Rich SJ
    J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S38-41. PubMed ID: 15253689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
    Alwawi EA; Krulig E; Gordon KB
    Dermatol Ther; 2009; 22(5):431-40. PubMed ID: 19845720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic dose assessment of patient switching from atorvastatin to simvastatin.
    Hess G; Sanders KN; Hill J; Liu LZ
    Am J Manag Care; 2007 Jun; 13 Suppl 3():S80-5. PubMed ID: 17596116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. And the beat goes on: formulary restriction, generic substitution, prior authorization, drug utilization, and now therapeutic interchange.
    Burkhart CG
    J Drugs Dermatol; 2004; 3(1):11. PubMed ID: 14964740
    [No Abstract]   [Full Text] [Related]  

  • 11. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry.
    Kumar A; Fonarow GC; Eagle KA; Hirsch AT; Califf RM; Alberts MJ; Boden WE; Steg PG; Shao M; Bhatt DL; Cannon CP;
    Crit Pathw Cardiol; 2009 Sep; 8(3):104-11. PubMed ID: 19726929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins.
    Jeske WP; Walenga JM; Hoppensteadt DA; Vandenberg C; Brubaker A; Adiguzel C; Bakhos M; Fareed J
    Semin Thromb Hemost; 2008 Feb; 34(1):74-85. PubMed ID: 18393144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing treatment with biologics.
    Mader R; Keystone E
    J Rheumatol Suppl; 2007 Nov; 80():16-24. PubMed ID: 17985419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managed care's perspective on treatment of plaque psoriasis.
    Sullivan TJ
    Manag Care; 2003 May; 12(5 Suppl):14-7; discussion 20-1. PubMed ID: 18564554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Addiction and brief-systemic therapy: working with compulsion].
    Cottencin O; Doutrelugne Y; Goudemand M; Consoli SM
    Encephale; 2009 Jun; 35(3):214-9. PubMed ID: 19540406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulatory and biologic therapies for severe refractory asthma.
    Polosa R; Morjaria J
    Respir Med; 2008 Nov; 102(11):1499-510. PubMed ID: 19012848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of early rheumatoid arthritis.
    Suresh E
    J Assoc Physicians India; 2007 May; 55():355-62. PubMed ID: 17844697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
    Foody JM; Joyce AT; Rudolph AE; Liu LZ; Benner JS
    Clin Ther; 2008 Jan; 30(1):195-205. PubMed ID: 18343257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.